SecBot SecBot
8-K ·Filed Jun 18, 2026

NVCR

NovoCure Ltd
BEARISH
Impact 6/10
Horizondays Processed5mo ago SEC0001645113-26-000053
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

Expect near-term selling pressure as the market prices in the failed label expansion opportunity. Monitor for any subsequent subgroup analyses or regulatory commentary that could partially offset the negative read.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.28
T+0 close · Jun 18, 2026 · via day close
Latest settled
+13.59%
T+60 · $16.22
Vs SPY
+11.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $14.28entry
  2. T+1 · 5mo ago −4.69%α −4.38% · $13.61
  3. T+5 · 5mo ago +5.39%α +7.06% · $15.05
  4. T+20 · 4mo ago +14.99%α +14.45% · $16.42
  5. T+60 · 2mo ago +13.59%α +11.69% · $16.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NovoCure announced that its Phase 3 TRIDENT trial failed to meet the primary endpoint of overall survival for earlier initiation of TTFields therapy in newly diagnosed glioblastoma. The median OS was nearly identical (17.7 vs 17.5 months, p=0.519), making this a clear negative read for the company's lead product expansion strategy.

Key Facts

  • Phase 3 TRIDENT trial did not demonstrate statistically significant improvement in overall survival for Early Start Arm vs Maintenance Start Arm (HR 0.953; p=0.519)
  • Median overall survival: 17.7 months (Early Start) vs 17.5 months (Maintenance Start)
  • One-, two-, and three-year survival rates were similar between arms (Early Start: 70.9%, 33.9%, 22.5%; Maintenance Start: 72.0%, 31.6%, 18.4%)
  • Trial enrolled 981 patients; no new safety signals observed
  • Results accepted for presentation at ASTRO 2026 Annual Meeting

Financial Impact

No financial data in filing; trial failure may reduce future revenue expectations for TTFields in GBM label expansion

Risk Factors

  • Potential negative read-through for other TTFields clinical trials (e.g., in NSCLC, pancreatic cancer)
  • Reduced growth expectations for the GBM franchise if earlier use is not adopted

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001645113-26-000053
Document: tridentdatapr.htm0001645113-26-000053
Document: 0001645113-26-000053-index-headers.html0001645113-26-000053
Document: 0001645113-26-000053-index.html0001645113-26-000053
Document: 0001645113-26-000053.txt0001645113-26-000053

Track record

20 reports on NVCR

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
  2. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  4. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
  6. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
  7. Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
  9. Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
  10. Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026